Plain-English translation of NCT06774690 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study that tracks how people with hepatocellular carcinoma or cholangiocarcinoma respond to intra-arterial therapies—treatments delivered directly into the arteries supplying the liver. Researchers will review medical images and treatment records from thousands of patients to understand what works best and what complications may arise.
Artery-targeted treatments are standard care for liver cancers, but doctors need better data on how effective they are across different patient groups and what side effects to watch for. This study gathers that real-world information to improve care.
You likely qualify if…
You likely don't qualify if…
If you join the prospective part of this study, you will receive your regular cancer treatment as planned—nothing changes about your care. You will attend follow-up visits every three months for up to five years, during which doctors will review your imaging scans and medical records to track how you are doing. If you are part of the retrospective review, researchers will examine your existing medical records and images from past treatments.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Italy
Enrollment target
~3,300 participants
Started
April 2021
Primary completion
March 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Cristina Mosconi, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.